ARHGEF19 promotes the growth of breast cancer in vitro and in vivo by the MAPK pathway

Abstract

Objective To assess the expression of ARHGEF19 in human breast cancer, investigate its role in breast cancer, and clarify the mechanism. Methods Bioinformatics analysis, immunoblot, quantitative PCR, and immunohistochemical (IHC) assays were performed to assess ARHGEF19 expression in breast cancer. CCK-8 and Edu assays were conducted to reveal its role in breast cancer cell proliferation. Flow cytometry (FCM) assays and immunoblot were performed to confirm its effects on breast cancer apoptosis. Immunoblot was also performed to clarify the mechanism. Finally, tumor growth assays were aimed to confirm the role of ARHGEF19 in mice. Results We observed that ARHGEF19 was highly expressed in human breast cancer. ARHGEF19 promoted breast cancer cell growth in vitro, and suppressed apoptosis. In addition, we found that ARHGEF19 could activate the MAPK pathway in breast cancer cells. Our findings further confirmed that ARHGEF19 contributed to breast cancer growth in mice. Conclusion We observed that ARHGEF19 promoted the growth of breast cancer in vitro and in vivo via MAPK pathway, and presume it could serve as a breast cancer therapeutic target.

Identification of SNP markers for canine mammary gland tumours in females based on a genome-wide association study – preliminary results

“…Studies showed that it played an important role in ovarian cancer by affecting cell proliferation and tumour sensitivity to therapy ( 34 ). Furthermore, the ARHGEF19 gene located on chromosome 2 and the LIMCH1 gene located on chromosome 13, within each of which we found one SNP ( TIGRP2P33447_rs8841788 and TIGRP2P176993_rs9197628 , respectively), were associated with an increased risk of breast cancer ( 3 , 30 ).…”